AtriCure (ATRC)
(Delayed Data from NSDQ)
$22.05 USD
+1.01 (4.80%)
Updated Aug 2, 2024 04:00 PM ET
After-Market: $22.04 -0.01 (-0.05%) 7:58 PM ET
3-Hold of 5 3
C Value B Growth F Momentum C VGM
Brokerage Reports
0 items in cart
AtriCure, Inc. [ATRC]
Reports for Purchase
Showing records 21 - 40 ( 59 total )
Company: AtriCure, Inc.
Industry: Medical - Products
Healthcare - 2Q 2012: Quarterly Medical Technology Trading & Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
Healthcare: Med Tech: The Vote Is In - ACA Upheld; Device Tax a Headwind into 2013
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MedTech Tax: Beyond the Headlines - What Device Tax Means to the Industry
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
Road Show Suggests Current Val''n Discounted; Long-Term Opp?s Unappreciated
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
Med Tech Earnings Wrap-Up: What Looks Good Out of 1Q12
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
Should Trade Higher - 1Q Growth Rebounds Above Estimates; Call 10AM ET
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
1Q Rebound & Solid Outlook-Should Trade with Higher Multiple;Reiterate Buy
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
1Q12 Medical Technology Earnings Preview Part 2
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
Healthcare - 1Q 2012: Quarterly Medical Technology Trading & Acquisition Valuation Update
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
Healthcare -Med Tech: Notes from the Podium - Highlights from the 2012 ROTH OC Conf
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
4Q Int?l Sales Strong; US Slow Until AF Kicks In; Maintain Buy
Provider: Roth Capital Partners, Inc.
Analyst: DOLAN M
Company: AtriCure, Inc.
Industry: Medical - Products
MORNING CALL SUMMARY
Provider: Roth Capital Partners, Inc.
Company: AtriCure, Inc.
Industry: Medical - Products
Company: AtriCure, Inc.
Industry: Medical - Products
Medical Technology: Keeping Things Simple as We Enter 2012 Already Weighed Down by Lingering Macro Uncertainties.
Provider: KAUFMAN BROTHERS
Analyst: CERVANTES V
Company: AtriCure, Inc.
Industry: Medical - Products
With AF FDA Label in Hand, ATRC Targets 500 More Cardiac Surgery Centers
Provider: KAUFMAN BROTHERS
Analyst: CERVANTES V